Phase 1 Psoriatic Arthritis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

General requirements (all participants):

• Adults between 18 and 75 years old
• Having a body weight of at least 45 kg (about 99 lbs) and a body mass index (a height-to-weight measure) between 18 and 40
• Using reliable contraception if able to become pregnant, or having a negative pregnancy test before joining

For Rheumatoid Arthritis (RA):

• Having a confirmed moderate to severe RA diagnosis for at least 3 months, with at least 6 swollen joints, at least 6 tender joints, certain proteins in the blood linked to RA, and elevated inflammation markers
• Having tried at least one standard RA medication that did not work well enough, caused side effects, or stopped working — but not having failed three or more of the advanced RA medications

For Psoriatic Arthritis (PsA):

• Having a confirmed PsA diagnosis for at least 3 months, with at least one active psoriasis skin patch and more than 3 swollen and 3 tender joints
• Having tried standard anti-inflammatory or disease-modifying medications, or being unable to tolerate them
• Having tried no more than one prior TNF-blocker medication

For Psoriasis (PsO):

• Having a confirmed moderate to severe plaque psoriasis diagnosis for at least 6 months, affecting more than 10% of the body surface, with specific severity scores above set thresholds
• Not having had a major flare-up of psoriasis in the past 12 weeks
• Having tried no more than two prior advanced (biologic) psoriasis medications that did not work

For Cutaneous Lupus Erythematosus (CLE — a skin form of lupus):

• Having a confirmed skin lupus diagnosis (proven by a skin biopsy) for at least 6 months, with active skin symptoms above a certain severity score
• Having tried antimalarial treatment (a common lupus medication) for at least 6 months without enough improvement

For Atopic Dermatitis (AD — a type of eczema):

• Having a confirmed eczema diagnosis for at least 12 months, affecting more than 10% of the body surface, with severity scores above set thresholds and significant itch
• Having tried topical (skin-applied) treatments for at least 4 weeks without enough improvement, or having had side effects from them, or having tried and failed other systemic treatments within the past 6 months

Who may not be able to join:

General exclusions (all participants):

• Having previously received certain immune system treatments, including checkpoint inhibitors, cell therapies, or B-cell or immune-depleting therapies (confirm with trial site)
• Having taken certain immune-suppressing medications (azathioprine, cyclosporine, mycophenolate mofetil, or tacrolimus) within the past 4 weeks
• Being unwilling or unable to stop taking any medications that are not allowed during the trial
• Currently having a significantly weakened immune system
• Currently having an infection or having a history of serious infections
• Having had any history of cancer, with some possible exceptions (confirm with trial site)

For CLE specifically:

• Having active kidney inflammation related to lupus, or having moderate-to-severe kidney disease
• Having active lupus affecting the brain or nervous system

Important: Always verify eligibility with the trial site directly before applying.